MTOR and non-small cell lung carcinoma: Numerous pre-clinical and retrospective clinical studies reported that Met treatment exerts its anti-neoplastic effects in sensitizing diabetic NSCLC patients to cytotoxic drug therapy on activation of the AMP-activated kinase pathway, an early growth signal transduction to counteract mTOR pathway activation in lipid and protein metabolism and in particular to promote apoptotic cancer death [48,49].